Literature DB >> 1345966

Eradicating Helicobacter pylori.

Y Glupczynski, A Burette.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1345966

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Effect of antimicrobial therapy on the specific serological response to Helicobacter pylori infection.

Authors:  Y Glupczynski; A Burette; H Goossens; C DePrez; J P Butzler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-07       Impact factor: 3.267

2.  Evaluation of a commercially available complement fixation test for diagnosis of Helicobacter pylori infection and for follow-up after antimicrobial therapy.

Authors:  H Goossens; Y Glupczynski; A Burette; C Van den Borre; C DePrez; J Bodenmann; A Keller; J P Butzler
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

3.  Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children.

Authors:  J Raymond; N Kalach; M Bergeret; P H Benhamou; J P Barbet; D Gendrel; C Dupont
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

4.  Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori.

Authors:  H Xia; C T Keane; S Beattie; C A O'Morain
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 5.  Clinical relevance of resistant strains of Helicobacter pylori: a review of current data.

Authors:  F Mégraud; H P Doermann
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

6.  Metronidazole susceptibility testing for Helicobacter pylori: comparison of disk, broth, and agar dilution methods and their clinical relevance.

Authors:  A J DeCross; B J Marshall; R W McCallum; S R Hoffman; L J Barrett; R L Guerrant
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.